Bodal Chemicals Q4 & FY26 Investor Presentation: Revenue Up 30% YoY in Q4
Bodal Chemicals reported Q4 FY26 revenue of ₹5,906 million (up 30% YoY) and EBITDA of ₹711 million (up 43% YoY). FY26 revenue was ₹20,539 million (up 16% YoY) with EBITDA at ₹2,028 million (up 19% YoY). Growth driven by volumes, realisations, and incentives. Basic Chemicals revenue up 80% YoY in FY26.
The investor presentation provides a detailed financial and operational update, including growth figures and segment performance, which is material information for investors. The growth in key segments like Basic Chemicals and the overall revenue increase positively impact investor sentiment.
The company has shown significant year-on-year growth in revenue and EBITDA for both Q4 FY26 and the full fiscal year FY26, driven by various business segments and strategic initiatives.
Bodal Chemicals Limited has released its investor presentation for the fourth quarter and full fiscal year 2026. In Q4 FY26, the company reported a total revenue of ₹5,906 million, marking a significant 30% year-on-year growth. The absolute EBITDA for the quarter stood at ₹711 million, an increase of 43% YoY.
For the full fiscal year FY26, the total revenue reached ₹20,539 million, a 16% growth on a YoY basis, with EBITDA at ₹2,028 million, up 19% YoY. This growth was driven by improved volumes, better realisations, and the recognition of SGST incentives from the Government of Punjab for their unit in Punjab. However, increased overheads from the Saykha plant partially offset profitability in other divisions.
The revenue from Dye Intermediates grew by 6%, Dyestuff by 6%, and Basic Chemicals by 80% YoY in FY26. In Q4 FY26, Dye Intermediates revenue increased by 21% YoY to ₹1,936 million, Dyestuffs revenue grew by 15% YoY to ₹1,441 million, and Basic Chemicals revenue surged by 239% YoY to ₹632 million, attributed to rising raw material and finished goods prices.
The Chlor Alkali business reported revenue of ₹3,387 million in FY26, remaining in line YoY, with ₹834 million in Q4 FY26. In Saykha's Benzene downstream products, Q4 FY26 saw satisfactory production levels, but margins were under pressure due to intense competition, subdued demand, and rising raw material prices. The company expects gradual growth and meaningful contributions from this segment on a QoQ basis.
Subsidiaries BCTPL and the Indonesian subsidiary performed satisfactorily in FY26. The Turkish subsidiary, Sener Boya, was impacted by hyperinflation. A loss of ₹26.5 million due to AS 29 in Q4 FY26 has been accounted for.
The management's ongoing rationalisation and monetisation of non-core assets have helped maintain cash flow and profitability. The company anticipates enhanced revenue and margins through improved volumes and the ability to pass on increased raw material costs.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.